views

Tissue Regenix – 2022 results, is it “achieving strong commercial traction”?

Previously writing on regenerative medical device group Tissue Regenix (TRX), I noted argues distribution agreement ‘delight’. How’s that balance sheet now?. The group has now announced results for the 2022 calendar year, arguing they with it “having delivered on its strategy for growth whilst achieving strong commercial traction”. What does that actually mean financially though?

views

Tissue Regenix – argues distribution agreement ‘delight’. How’s that balance sheet now?

Regenerative medical device group Tissue Regenix (TRX) has announced it is “delighted to be partnering with Kingsung Medical”for the distribution of OrthoPure XT in China. With its shares currently up by more than 7% on the day at 0.69p – with so many in issue, a £48.5 million market cap, what’s the significance?

views

Tissue Regenix – “product launch” & “distribution agreement”, ramptastic?

Regenerative medical device company Tissue Regenix (TRX) states “following the successful launch of VNEW with ARMS Medical in September 2021, we are very pleased to be continuing our partnership and launching the VNEW Fascia Lata allograft for surgical procedures to support tissue”. So what of a share price response slightly lower to 0.575p?

views

Tissue Regenix – interims, robust financial and operational performance?

Previously writing on company which describes itself as “a leading medical device company in the field of regenerative medicine” Tissue Regenix (TRX), in January I questioned “robust financial and operational performance”. So what of now results for the first half of 2022?

views

Tissue Regenix – argues “delivered robust financial and operational performance”. Has it?...

Describing itself as “a leading medical devices company in the field of regenerative medicine” Tissue Regenix (TRX) has made a full-year trading update headlined “Return to double digit growth in 2021” and concluding “the company has delivered robust financial and operational performance”. Why then are the shares still below 0.50p, compared to above 1.2p in May 2020?...

views

Tissue Regenix – is it really “strong H1 results” & “a strong cash position” from this former Neil Woodford dog?

Tissue Regenix (TRX) has announced results for the first half of 2021 claiming “we have created a commercially focussed regenerative global medtech company in a high growth sector… encouraged by our strong H1 results” and that we “look forward to this being further built on in H2”. So why are the shares, at 0.675p, currently more than 4% lower?

views

Tissue Regenix – I having warned of still a required fundraising ahoy...

I first warned on shares in Tissue Regenix (TRX) in October as they fell below 3p and most recently above 1p earlier this month, noting still a required fundraising ahoy. Today an announcement; “Confirmation of successful fundraising”...

NEWSFLOW

Tissue Regenix (#TRX) – raises £14.6m at 0.25p per share including via PrimaryBid

views

Tissue Regenix – “New collaboration” announcement from this Woodford pick ramptastic?...

An announcement from ‘regenerative medicine medical devices company’ Tissue Regenix (TRX) – and the shares currently above 1p, more than 55% higher. Though “New collaboration with leading healthcare company” ramptastic?...

views

Tissue Regenix – I having questioned what about the balance sheet of this Woodford pick?...

‘Regenerative medicine’ medical devices company Tissue Regenix (TRX) has updated including that currently “the San Antonio facility remains fully operational” and the company “has not experienced any material reduction in net revenues versus expectations”. However, the shares have currently responded to below 0.40p, circa 35% lower…